SynAct expanded its melanocortin agonist portfolio through the acquisition of TXP Pharma AG. TXP Pharma was a privately held, Swiss-incorporated biotech company researching and developing pharmaceutical drugs for autoimmune and inflammatory diseases by stimulation of melanocortin receptors. TXP Pharma has created a platform of more than 70 unique analogues of the naturally occurring melanocyte stimulation hormone (MSH) with a range of melanocortin receptor selectivity. The TXP-analogues have both increased stability as well as enhanced receptor binding and stimulation over MSH.
TXP Peptides Provide the Opportunity to Develop Unique Assets Tailored to the Target Disease and Patient Population